MARKSANS329.00

Marksans Pharma Ltd.

· Pharma & Health
₹ CrorePeersGRANULESMETROPOLISPARKHOSPSJLHLHCGRUBICONSHILPAMEDSPARCMcap ₹14,909 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)337.80409.83369.97369.97
Receivable Days (DSO)75.9775.1579.7379.73
Payable Days (DPO)146.65148.18128.20124.57
Cash Conversion Cycle (days)267.12336.80321.50325.13
Working Capital Turnover1.481.521.341.44
Asset Turnover0.810.810.760.76
Cash Conversion (CFO/Net Income)0.730.541.091.09
CFO/EBITDA0.500.390.760.76
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.